HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Latest Hornedine Find Is On Texas Firm’s Supplement Labels During Website Inspection

Executive Summary

Hornedine isn’t an “old” dietary ingredient exempt from pre-market notification with proof its safety because it wasn’t available in the US food supply before October 1994. "T

You may also be interested in...



Court Suggests Critics Ask Congress To Change FDA's GRAS Rule – Same For NDI Notifications?

Federal judge suggests consumer health and environmental advocacy groups made strong arguments about potential for unsafe ingredients in foods available in the US through the self-GRAS process, but FDA adopted and exercises the rule entirely in line with congressional intent of the authorizing legislation.

US Supplement Firm Shut Down By Decree After Using Ingredient On FDA ‘Advisory List'

FDA's decree of permanent injunction with Fusion Health and Vitality filed same day the firm announced recall of its Core Essential Nutrients and Immune Boost Sublingual Vitamin D3 products found to contain hordenine HCl.

US FDA-Funded Study Spurs Consumer Reports’ Latest Lament On VMS Market Oversight

Abstract of study notes methylsynephrine and isopropyloctopamine found in bitter orange supplements aren’t permitted by FDA as dietary ingredients. CR says despite the findings, FDA hasn't enforced against manufacturers or warned consumers.

Related Content

Topics

UsernamePublicRestriction

Register

RS151917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel